Skip to main content
Erschienen in: Journal of Neurology 3/2016

01.03.2016 | Original Communication

Impact of Angiotensin-II receptor blockers on vasogenic edema in glioblastoma patients

verfasst von: Antoine Kourilsky, Guillaume Bertrand, Renata Ursu, Jennifer Doridam, Ciprian Barlog, Thierry Faillot, Emmanuel Mandonnet, Catherine Belin, Christine Levy, Antoine F. Carpentier

Erschienen in: Journal of Neurology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Glioblastoma patients often require chronic administration of steroids due to peri-tumoral edema. Preliminary studies showed that treatment with Angiotensin-II Receptor Blockers (ARBs) for high blood pressure might be associated with reduced peri-tumoral edema. In this study, we aim to radiologically assess the effect of ARBs on peri-tumoral edema. We conducted a cross-sectional survey on patients with newly diagnosed GBM. Patients treated with ARBs for high blood pressure were paired to non ARB-treated patients based on similar age, tumor location and tumor size. Patients taking steroids at the time of pre-operative Magnetic Resonance Imaging were excluded from the study. In each pair of patients, we compared the volumes of peri-tumoral hyper T2-Fluid Attenuated Inversion Recovery (FLAIR) signal and the Apparent Diffusion Coefficient (ADC) in the same area. Eleven (11) ARB-treated patients were selected and paired to 11 non ARB-treated controls. Volumes of peri-tumoral hyper T2-FLAIR signal were significantly lower in the ARB-treated group than in the non ARB-treated group (p = 0.02). Additionally, peri-tumoral ADCs were also significantly lower in the treated group (p = 0.02), suggesting that the peri-tumoral area in this group had less edematous features. These results suggest that ARBs may reduce the volume of peri-tumoral hyper T2-FLAIR signal by decreasing edema.
Literatur
1.
Zurück zum Zitat Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed
2.
Zurück zum Zitat Marantidou A, Levy C, Duquesne A, Ursu R, Bailon O, Coman I et al (2010) Steroid requirements during radiotherapy for malignant gliomas. J Neurooncol 100:89–94CrossRefPubMed Marantidou A, Levy C, Duquesne A, Ursu R, Bailon O, Coman I et al (2010) Steroid requirements during radiotherapy for malignant gliomas. J Neurooncol 100:89–94CrossRefPubMed
3.
Zurück zum Zitat Hempen C, Weiss E, Hess CF (2002) Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? Support Care Cancer 10:322–328CrossRefPubMed Hempen C, Weiss E, Hess CF (2002) Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? Support Care Cancer 10:322–328CrossRefPubMed
4.
Zurück zum Zitat Deshayes F, Nahmias C (2005) Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16:293–299CrossRefPubMed Deshayes F, Nahmias C (2005) Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16:293–299CrossRefPubMed
5.
Zurück zum Zitat Fogarty DJ, Sánchez-Gómez MV, Matute C (2002) Multiple angiotensin receptor subtypes in normal and tumor astrocytes in vitro. Glia 39:304–313CrossRefPubMed Fogarty DJ, Sánchez-Gómez MV, Matute C (2002) Multiple angiotensin receptor subtypes in normal and tumor astrocytes in vitro. Glia 39:304–313CrossRefPubMed
6.
Zurück zum Zitat Juillerat-Jeanneret L, Gasc J-M, Corvol P (2004) The renin-angiotensin system in human brain and brain tumors: a function unrelated to blood pressure control? Bull Acad Natl Med 188:639–646 (discussion 647–648) PubMed Juillerat-Jeanneret L, Gasc J-M, Corvol P (2004) The renin-angiotensin system in human brain and brain tumors: a function unrelated to blood pressure control? Bull Acad Natl Med 188:639–646 (discussion 647–648) PubMed
7.
Zurück zum Zitat Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M (2002) Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 294:441–447CrossRefPubMed Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M (2002) Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 294:441–447CrossRefPubMed
8.
Zurück zum Zitat Egami K, Murohara T, Shimada T, Sasaki K-I, Shintani S, Sugaya T et al (2003) Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112:67–75CrossRefPubMedPubMedCentral Egami K, Murohara T, Shimada T, Sasaki K-I, Shintani S, Sugaya T et al (2003) Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112:67–75CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Imai N, Hashimoto T, Kihara M, Yoshida S, Kawana I, Yazawa T et al (2007) Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis. Lab Invest 87:189–198CrossRefPubMed Imai N, Hashimoto T, Kihara M, Yoshida S, Kawana I, Yazawa T et al (2007) Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis. Lab Invest 87:189–198CrossRefPubMed
10.
Zurück zum Zitat Rivera E, Arrieta O, Guevara P, Duarte-Rojo A, Sotelo J (2001) AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma. Br J Cancer 85:1396–1399CrossRefPubMedPubMedCentral Rivera E, Arrieta O, Guevara P, Duarte-Rojo A, Sotelo J (2001) AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma. Br J Cancer 85:1396–1399CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD et al (1996) Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98:671–679CrossRefPubMedPubMedCentral Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD et al (1996) Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98:671–679CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Arrieta O, Guevara P, Escobar E, García-Navarrete R, Pineda B, Sotelo J (2005) Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer 92:1247–1252CrossRefPubMedPubMedCentral Arrieta O, Guevara P, Escobar E, García-Navarrete R, Pineda B, Sotelo J (2005) Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer 92:1247–1252CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Ando H, Jezova M, Zhou J, Saavedra JM (2004) Angiotensin II AT1 receptor blockade decreases brain artery inflammation in a stress-prone rat strain. Ann N Y Acad Sci 1018:345–350CrossRefPubMed Ando H, Jezova M, Zhou J, Saavedra JM (2004) Angiotensin II AT1 receptor blockade decreases brain artery inflammation in a stress-prone rat strain. Ann N Y Acad Sci 1018:345–350CrossRefPubMed
14.
Zurück zum Zitat Zhang M, Mao Y, Ramirez SH, Tuma RF, Chabrashvili T (2010) Angiotensin II induced cerebral microvascular inflammation and increased blood-brain barrier permeability via oxidative stress. Neuroscience 171:852–858CrossRefPubMed Zhang M, Mao Y, Ramirez SH, Tuma RF, Chabrashvili T (2010) Angiotensin II induced cerebral microvascular inflammation and increased blood-brain barrier permeability via oxidative stress. Neuroscience 171:852–858CrossRefPubMed
15.
Zurück zum Zitat Sano H, Hosokawa K, Kidoya H, Takakura N (2006) Negative regulation of VEGF-induced vascular leakage by blockade of angiotensin II type 1 receptor. Arterioscler Thromb Vasc Biol 26:2673–2680CrossRefPubMed Sano H, Hosokawa K, Kidoya H, Takakura N (2006) Negative regulation of VEGF-induced vascular leakage by blockade of angiotensin II type 1 receptor. Arterioscler Thromb Vasc Biol 26:2673–2680CrossRefPubMed
16.
Zurück zum Zitat Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T et al (1999) Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 9:53–60CrossRefPubMed Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T et al (1999) Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 9:53–60CrossRefPubMed
17.
Zurück zum Zitat Chien D, Kwong KK, Gress DR, Buonanno FS, Buxton RB, Rosen BR (1992) MR diffusion imaging of cerebral infarction in humans. AJNR Am J Neuroradiol 13:1097–1102 (discussion 1103–1105) PubMed Chien D, Kwong KK, Gress DR, Buonanno FS, Buxton RB, Rosen BR (1992) MR diffusion imaging of cerebral infarction in humans. AJNR Am J Neuroradiol 13:1097–1102 (discussion 1103–1105) PubMed
18.
Zurück zum Zitat Brunberg JA, Chenevert TL, McKeever PE, Ross DA, Junck LR, Muraszko KM et al (1995) In vivo MR determination of water diffusion coefficients and diffusion anisotropy: correlation with structural alteration in gliomas of the cerebral hemispheres. AJNR Am J Neuroradiol 16:361–371PubMed Brunberg JA, Chenevert TL, McKeever PE, Ross DA, Junck LR, Muraszko KM et al (1995) In vivo MR determination of water diffusion coefficients and diffusion anisotropy: correlation with structural alteration in gliomas of the cerebral hemispheres. AJNR Am J Neuroradiol 16:361–371PubMed
19.
Zurück zum Zitat Els T, Eis M, Hoehn-Berlage M, Hossmann KA (1995) Diffusion-weighted MR imaging of experimental brain tumors in rats. MAGMA 3:13–20CrossRefPubMed Els T, Eis M, Hoehn-Berlage M, Hossmann KA (1995) Diffusion-weighted MR imaging of experimental brain tumors in rats. MAGMA 3:13–20CrossRefPubMed
20.
Zurück zum Zitat Tien RD, Felsberg GJ, Friedman H, Brown M, MacFall J (1994) MR imaging of high-grade cerebral gliomas: value of diffusion-weighted echoplanar pulse sequences. AJR Am J Roentgenol 162:671–677CrossRefPubMed Tien RD, Felsberg GJ, Friedman H, Brown M, MacFall J (1994) MR imaging of high-grade cerebral gliomas: value of diffusion-weighted echoplanar pulse sequences. AJR Am J Roentgenol 162:671–677CrossRefPubMed
21.
Zurück zum Zitat Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS et al (2010) Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging 31:538–548CrossRefPubMedPubMedCentral Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS et al (2010) Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging 31:538–548CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Tom B, Dendorfer A, de Vries R, Saxena PR, Jan Danser AH (2002) Bradykinin potentiation by ACE inhibitors: a matter of metabolism. Br J Pharmacol 137:276–284CrossRefPubMedPubMedCentral Tom B, Dendorfer A, de Vries R, Saxena PR, Jan Danser AH (2002) Bradykinin potentiation by ACE inhibitors: a matter of metabolism. Br J Pharmacol 137:276–284CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Carpentier AF, Ferrari D, Bailon O, Ursu R, Banissi C, Dubessy A-L et al (2012) Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients. Eur J Neurol 19:1337–1342CrossRefPubMed Carpentier AF, Ferrari D, Bailon O, Ursu R, Banissi C, Dubessy A-L et al (2012) Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients. Eur J Neurol 19:1337–1342CrossRefPubMed
25.
Zurück zum Zitat Fleegal-DeMotta MA, Doghu S, Banks WA (2009) Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells. J Cereb Blood Flow Metab 29:640–647CrossRefPubMed Fleegal-DeMotta MA, Doghu S, Banks WA (2009) Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells. J Cereb Blood Flow Metab 29:640–647CrossRefPubMed
26.
Zurück zum Zitat Wosik K, Cayrol R, Dodelet-Devillers A, Berthelet F, Bernard M, Moumdjian R et al (2007) Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J Neurosci 27:9032–9042CrossRefPubMed Wosik K, Cayrol R, Dodelet-Devillers A, Berthelet F, Bernard M, Moumdjian R et al (2007) Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J Neurosci 27:9032–9042CrossRefPubMed
27.
Zurück zum Zitat Li Z, Cao Y, Li L, Liang Y, Tian X, Mo N et al (2014) Prophylactic angiotensin type 1 receptor antagonism confers neuroprotection in an aged rat model of postoperative cognitive dysfunction. Biochem Biophys Res Commun 449:74–80CrossRefPubMed Li Z, Cao Y, Li L, Liang Y, Tian X, Mo N et al (2014) Prophylactic angiotensin type 1 receptor antagonism confers neuroprotection in an aged rat model of postoperative cognitive dysfunction. Biochem Biophys Res Commun 449:74–80CrossRefPubMed
Metadaten
Titel
Impact of Angiotensin-II receptor blockers on vasogenic edema in glioblastoma patients
verfasst von
Antoine Kourilsky
Guillaume Bertrand
Renata Ursu
Jennifer Doridam
Ciprian Barlog
Thierry Faillot
Emmanuel Mandonnet
Catherine Belin
Christine Levy
Antoine F. Carpentier
Publikationsdatum
01.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 3/2016
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-015-8016-9

Weitere Artikel der Ausgabe 3/2016

Journal of Neurology 3/2016 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.